Background: No gold standard assay for serum total thyroxine (TT4) concentration in small animals exists. The Microgenics DRI TT4 (MTT4) assay is used by most reference laboratories.
K E Y W O R D S chemiluminescence, enzyme immunoassay, hyperthyroidism, hypothyroidism 1 | INTRODUCTION Thyroid disorders are important endocrine diseases in companion animals with a prevalence of up to 0.8% in dogs 1 and 2% in cats. 2 The diagnosis of hypothyroidism in dogs is complicated by a number of factors including euthyroid sick syndrome, which causes a decrease in the measured serum total thyroxine (TT4) concentration in the presence of non-thyroidal illness. 3, 4 Euthyroid sick syndrome also may complicate the diagnosis of hyperthyroidism in cats. 5 Radioimmunoassay and chemiluminescent techniques have been validated for measurement of TT4 in dogs and cats. 6, 7 The Microgenics DRI TT4 enzyme immunoassay (EIA) designed for use in humans (MTT4; Microgenics Corporation, Fremont, California) is the assay most commonly used by commercial reference laboratories. This assay recently has been validated for use in healthy cats, 8 but validation has not been published in dogs. The previously developed Microgenics CEDIA TT4 EIA for humans was validated for cats and dogs against radioimmunoassay. 9 Validation of the Immulite 1000 chemiluminescent TT4 assay (Siemens Healthineers USA) has been published in both dogs 10 and cats. 2 These studies frequently have been cited in other published studies of thyroid function in dogs and cats. [11] [12] [13] [14] The Immulite 2000 TT4 assay (ITT4; Siemens Healthineers USA) has been used to measure TT4 in dogs and cats, but full validation of this assay has not been published. 15, 16 The MTT4 and ITT4 assays are both commonly utilized in commercial laboratories. The MTT4 assay has been evaluated for linearity, precision, accuracy, analytical range, and detection limits in healthy animals and those affected with hypothyroidism or hyperthyroidism (G. Bilbrough, personal communication), but in most cases this information has not been published in the peer-reviewed literature.
A novel dry-slide TT4 assay (CTT4; Catalyst Total T4 Test, IDEXX Laboratories, Inc, Westbrook, Maine) recently was introduced for in-clinic use using 2 bench top point-of-care analyzers (IDEXX Catalyst One Analyzer [C1]; IDEXX Catalyst Dx Analyzer [CDx] ). The CTT4 assay has been compared previously to the MTT4 assay using sera from untreated hyperthyroid and 131 I-treated hyperthyroid cats with favorable agreement, coefficient of variation (CV), and linearity. 17 Guidelines from the American Society for Veterinary Clinical Pathology (ASVCP) state that comparative testing for quality assurance between established methods and newly developed methods should be performed to assess whether constant bias or proportional bias exist that could interfere with clinical interpretation of results. 18 We hypothesized that the CTT4 and ITT4 in dogs and cats would be equivalent to the MTT4 for clinically relevant TT4 test results. Our objectives were (1) following the normal laboratory protocol. All samples were stored at −80 C for up to 33 days until aliquoted. IDEXX Laboratories approved the use of these residual serum samples for research purposes.
Samples with insufficient volume were excluded. Individual samples were removed from storage, thawed at room temperature for 5 minutes, and transferred into new tubes that were labeled only with random numbers by 1 investigator (E.D.S.W.), and stored again at −80 C for 3.5 to 7.5 months. Batches of serum samples later were thawed and tested using multiple assays (CTT4 versus MTT4 and ITT4 versus MTT4 study arms) at the same time without intervening freeze-thaw cycles. Samples therefore were subjected to 2 freezethaw cycles (1 after initial sample submission for randomization and another after sample randomization) before the final round of testing, which took place a maximum of 233 days after initial sampling. To ensure that a full range of TT4 concentrations would be included, the tubes containing residual serum were organized into groups, which contained low, low-normal, high-normal, and high TT4 concentrations, respectively, based on initial MTT4 results and clinical cut points from the reference laboratory (Table 1) . Samples were chosen with the aim of achieving a minimum of 40 samples per typical TT4 concentration group for each species for the comparison between the IDEXX Catalyst TT4 assay run on either the C1 or CDx analyzer (IDEXX Laboratories) and the MTT4 assay, and a minimum of 20 samples per typical TT4 concentration group for the ITT4 to MTT4 comparison. Samples with paired results differing by >50% (strongly discordant results) were assessed to determine whether there was possible laboratory error or if the difference was related to results beyond detection limits.
| Validation
Validation was performed for the CTT4 and MTT4 assays in dogs. To determine precision, guidelines from the Clinical and Laboratory Standards Institute (CLSI) EP05 were utilized. 17, 20 For intra-assay variability, 5 replicate TT4 measurements were performed on 3 serum pools on the same day and CV was calculated. Inter-assay variability was calculated from 20 replicate samples taken from 4 serum pools analyzed on 5 days. Linearity and limits of the blank also were determined using CLSI guidelines which have been described in depth using the same protocol. 17 
| Statistical analysis
Statistical analyses included calculation of the Pearson correlation coefficient (r), and the Passing-Bablok linear regression to measure constant and proportional bias. 21, 22 Cumulative sum (CUSUM) linearity was assessed in the Passing-Bablok regression because of the assumption of linearity for this regression model. 23 If the CUSUM test for linearity indicated significant deviation, then piecewise/segmented regression was performed, which determined a y-intercept and slope for an initial linear segment, a breakpoint/knot, and a slope for a second linear segment proceeding from the breakpoint. 24 Bland-Altman plots were performed to compare the difference in measured serum TT4 concentration to the average concentration for the MTT4 versus CTT4 and MTT4 versus ITT4 comparisons in both cats and dogs. 25, 26 
| RESULTS
The specimens for all method comparisons were drawn from samples submitted from the northeast United States. Signalment, other demographic information, and history pertinent to submitted samples were not available for evaluation. Sample size information for each species and concentration group is summarized in Table 1 . Figure 1A , Table 2 ). The slope of the Passing-Bablok regression was 0.86 (95% CI, 0.83-0.89; Figure 1A , Figure 2A , Table 2 ). The slope of the regression was 0.76 (95% CI, 0.72-0.80), indicating significant proportional bias was present (Figure 2A , Table 2 ). The Bland-Altman plots 
| Cats
The CTT4 assay previously has been validated for cats. Intra-assay variability had a mean of 2.8%, inter-assay variability had a mean of 6.6%, and the assay was linear from 0 to 11.65 μg/dL (0-149.96 nmol/L). 17 Published CV data from MTT4 validation in cats showed inter-and intra-assay variability <12%, and the assay was linear from 0.44 to 11.73 μg/dL (5.66 to 150.99 nmol/L). 8 Published CV data from ITT4 validation in cats showed intra-assay variability of 14.5% at a mean of Figure 3B ), greatest variation in TT4 results between the 2 analyzers was noted in MTT4 concentrations >11 μg/dL (141.59 nmol/L).
| ITT4 versus MTT4
After excluding a single strongly discordant result (>6-fold difference) as a possible laboratory error, 19 Another important consideration in the evaluation of assays is biological variation among animals (coefficient of variation, individual
[CVi]). Quality assurance goals for TT4 attempt to show that the CV from assay results is not due simply to biological variation. Differences derived from CVi have been reported previously as 2.9% to 8.6% for cats 30 and 4.25% to 12.75% for dogs. 31 This suggests that the CTT4 in cats is just below the low threshold of quality goals (which is not a relevant difference), the MTT4 is within the range of quality goals, and the ITT4 also is within the range of historically assessed quality goals based on CVi. In dogs, the CTT4 and MTT4 are within the established quality goals for TT4, but the ITT4 CVi at 14.25% falls outside the quality goals.
With in-clinic testing, frequent quality control monitoring is necessary to maintain testing standards. The in-clinic CTT4 assay used in our study was performed in a reference laboratory setting by labora- 
